The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage study. GSK's renewed application is based on two late-stage trials showing that Blenrep, when used in combination, improved overall survival in patients.

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations. The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.